Neovacs SA (FR:ALNEV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neovacs SA, a French biopharmaceutical company specializing in inflammatory and autoimmune diseases, has declined to provide additional financial support to Pharnext’s creditor compensation plan, avoiding an investment of nearly 9 million euros. The company’s Board has also executed share capital operations to meet tax criteria for innovation aid, including capital increases and a significant reduction of the nominal share value from 7.00 euros to 0.005 euro.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.